Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Opioid Analgesic Combination/Discontinued

DARVOCET

DARVOCET

Clinical safety rating

caution

Comprehensive clinical and safety monograph for DARVOCET (DARVOCET).


Mechanism of Action

Darvocet is a combination of propoxyphene, a mu-opioid receptor agonist that alters perception of and response to pain, and acetaminophen, which inhibits COX enzymes and modulates descending serotonergic pathways.

What the body does with it

MetabolismPropoxyphene: extensively metabolized via CYP3A4 to norpropoxyphene (active metabolite); Acetaminophen: metabolized primarily via glucuronidation and sulfation, with minor CYP2E1 oxidation.
ExcretionPropoxyphene: primarily hepatic metabolism to norpropoxyphene, renal excretion of metabolites (<1% unchanged). Acetaminophen: renal excretion of conjugates (85-90%) and unchanged drug (2-4%).
Half-lifePropoxyphene: 6-12 hours (parent), 30-36 hours (norpropoxyphene). Acetaminophen: 1-4 hours (therapeutic doses). Accumulation of norpropoxyphene occurs with repeated dosing.
Protein bindingPropoxyphene: 80% bound to albumin. Acetaminophen: 10-25% bound to albumin.
Volume of DistributionPropoxyphene: 10-16 L/kg (large due to lipophilicity). Acetaminophen: 0.9-1.0 L/kg (distributes evenly in body fluids).
BioavailabilityPropoxyphene: oral bioavailability ~40% due to first-pass metabolism. Acetaminophen: oral bioavailability 80-90%.
Onset of ActionOral: propoxyphene peak effect at 1-2 hours; acetaminophen peak effect at 30-60 minutes.
Duration of ActionPropoxyphene: 4-6 hours (analgesia). Acetaminophen: 4-6 hours (antipyretic/analgesic). Norpropoxyphene prolongs potential toxicity.
Molecular Weight339.48

Classification & Brands

Brand SubstitutesCaybutyl 650 mg/65 mg Tablet, Corbutyl 650mg/65mg Tablet, Kortyl 650mg/65mg Tablet, Paraphen 650mg/65mg Tablet

Dosing & administration

1 tablet (propoxyphene 100 mg / acetaminophen 650 mg) orally every 4 hours as needed for pain; maximum 6 tablets per day.

Dosage formTABLET
Renal impairmentFor creatinine clearance <50 mL/min: avoid use; propoxyphene accumulates causing CNS and cardiac toxicity. For 50–80 mL/min: reduce frequency to every 6 hours. Not recommended in ESRD or dialysis.
Liver impairmentChild-Pugh Class A: cautious use, reduce dose by 50% and monitor. Child-Pugh Class B or C: contraindicated due to risk of hepatotoxicity from acetaminophen and altered propoxyphene metabolism.
Pediatric useNot recommended for pediatric use due to risk of serious adverse effects; safety and efficacy not established.
Geriatric useStart with 1 tablet (100/650 mg) every 6 hours; maximum 4 tablets per day. Avoid in patients with renal impairment or multiple comorbidities. Increased risk of CNS depression and falls.

Use during pregnancy

1st trimesterAvoid use due to risk of teratogenicity; acetaminophen component considered safe but propoxyphene associated with neonatal withdrawal and possible malformations.
2nd trimesterAvoid use; no clear evidence of safety during organogenesis; propoxyphene may cause fetal dependence.
3rd trimesterAvoid use near term; propoxyphene can cause neonatal respiratory depression and withdrawal syndrome.

Clinical note

Comprehensive clinical and safety monograph for DARVOCET (DARVOCET).

Placental transferBoth acetaminophen and propoxyphene cross the placenta. Propoxyphene achieves fetal/maternal ratios of 0.8-0.9, indicating significant transfer.
BreastfeedingPropoxyphene is excreted into breast milk in low concentrations; however, due to the risk of neonatal respiratory depression and sedation, breastfeeding is generally not recommended. Consider alternative analgesics with better safety profiles.
Lactation RatingL4 (Possibly Hazardous)
Teratogenic RiskPregnancy Category C. First trimester: No evidence of structural malformations from acetaminophen; propoxyphene has not been associated with increased risk of major birth defects. Second and third trimesters: Chronic use may lead to neonatal withdrawal syndrome (irritability, hypertonia, tremors) and respiratory depression. High-dose or prolonged use near term associated with neonatal respiratory depression.
Fetal MonitoringMonitor maternal liver function tests and renal function in prolonged use. Fetal: Nonstress test and biophysical profile if used chronically in third trimester. Neonatal: Observe for signs of withdrawal if used near term.
Fertility EffectsNo adequate studies on fertility. Propoxyphene may impair ovulation and sperm motility based on animal data; clinical significance unknown.

Warnings & precautions

■ FDA Black Box Warning

Propoxyphene has been withdrawn from the US market due to risk of fatal overdose; Darvocet is no longer available in the US.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to propoxyphene or acetaminophenKnown propoxyphene abuse or dependenceSignificant respiratory depressionAcute or severe bronchial asthmaConcurrent use of MAO inhibitors or within 14 daysSuicidal ideation or actions

Clinical Precautions

PrecautionsRespiratory depression, QT prolongation (propoxyphene), hepatotoxicity (acetaminophen at high doses), abuse potential, interaction with alcohol and CNS depressants.
Food/DietaryAvoid alcohol. No specific food interactions, but take with food if gastrointestinal upset occurs. Maintain adequate hydration and fiber intake to prevent constipation.

Clinical Tips & Counseling

Clinical PearlsDarvocet contains propoxyphene, a weak opioid with potential for cardiac toxicity (QT prolongation) at high doses. Avoid in patients with history of substance abuse, suicidal ideation, or concurrent use of CNS depressants. Efficacy similar to aspirin, but with higher risk of adverse effects; consider safer alternatives. Monitor for respiratory depression in elderly or debilitated patients.
Patient AdviceTake exactly as prescribed; do not take more than recommended dose. · Avoid alcohol and other CNS depressants (e.g., benzodiazepines) as they increase risk of serious side effects. · Do not drive or operate heavy machinery until you know how this medication affects you. · Do not stop abruptly; withdrawal may occur. Taper under medical supervision. · Report severe constipation, difficulty breathing, or signs of allergic reaction. · Store securely away from children and others; dispose properly when no longer needed.

DARVOCET Interactions

Loading safety data…

This overview is compiled from peer-reviewed clinical sources and FDA labeling. It's here to support — not replace — clinical judgment. Always verify dosing against your institution's current protocols before prescribing.

On this page

Mechanism of ActionDosing & administrationUse during pregnancyWarnings & precautionsDrug interactions

Compare with

ANEXSIAANEXSIA 5/325ANEXSIA 7.5/325ANEXSIA 7.5/650ATROPINE AND DEMEROL

External sources

DailyMed (NIH) PubMed OpenFDA